Retension Pharmaceuticals: director Donald Olds received 5,636 shares

What happened Donald Olds, a director, received 5,636 shares as a derivative award on Oct 8, 2026. The filing lists the acquisition price as $0.00 per share, total $0, and is reported on a Form 4 filed Oct 8, 2026.

Key details

• Transaction date and price: Oct 8, 2026; $0.00 per share; total $0.
• Transaction code: A (award/grant).
• Shares owned after the transaction: not reported on the Form 4.
• Footnote: option award granted pursuant to the issuer's 2026 equity incentive plan. 25% of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the reporting person's continued service on each vesting date.
• Filing timeliness: no late filing indicated (Form 4 dated Oct 8, 2026).

Why it may matter

• The filing shows an option award (a derivative grant), not an exercise or a market sale.
• This was not a market trade or a gift as reported on the Form 4.
• A filing does not show why the insider traded or why the company acted.